Medical Supplies

Vizient Task Force Releases Recommendations for Hospitals on Preparing for an Active Shooter Event

Retrieved on: 
Tuesday, April 2, 2024
Science, Public Policy, Government, Practice Management, Research, Medical Supplies, Health, Law Enforcement, Emergency Services, Hospitals, Organization, Communication, Disaster medicine, Risk, Patient, American Journal, Hospital, Trauma, Hope, Bleeding, Hospice and palliative medicine, Safety, Language, Risk management

Vizient, Inc. released recommendations focused on mitigating common risks, identifying national guidelines and utilizing existing resources to ensure preparedness for an active shooter event.

Key Points: 
  • Vizient, Inc. released recommendations focused on mitigating common risks, identifying national guidelines and utilizing existing resources to ensure preparedness for an active shooter event.
  • The recommendations were made by a task force of 40 Vizient network executives from 27 organizations across the country.
  • The recommendations and rationales bring attention to organizational tactics that were found by the task force to be lacking or inconsistent.
  • “It is an uncomfortable topic to discuss but it is vital that hospitals address the issue of a potential active shooter event,” said Susan Chishimba, Vizient Member Networks senior director.

Watchmaker Genomics Announces Launch of Cost-effective RNase Inhibitor for Single-cell, Single-nuclei, and Pathogen Detection Applications

Retrieved on: 
Tuesday, April 2, 2024
Medical Supplies, Medical Devices, Health, Genetics, Other Health, Biotechnology, Watchmaker, Marketing, Ribonuclease, RNA, Genomics, Pharmaceutical industry

Watchmaker Genomics, a provider of innovative solutions for molecular analysis, announced the launch of a high-purity RNase Inhibitor that is well-suited for a wide range of applications where maintaining RNA integrity is critical, including single-cell and single-nuclei sequencing, as well as pathogen detection.

Key Points: 
  • Watchmaker Genomics, a provider of innovative solutions for molecular analysis, announced the launch of a high-purity RNase Inhibitor that is well-suited for a wide range of applications where maintaining RNA integrity is critical, including single-cell and single-nuclei sequencing, as well as pathogen detection.
  • “We are pleased to bring our RNase Inhibitor to market,” said Sandra Rowe, Vice President of Marketing at Watchmaker.
  • “We aim to be a partner for our customers and provide high-performing yet cost-effective solutions to allow for higher throughput and increased sensitivity.”
    Key features of Watchmaker’s RNase Inhibitor include:
    The launch of the RNase Inhibitor complements Watchmaker’s Precision Enzymes portfolio, which includes the highly thermostable and inhibitor-tolerant StellarScript HT+ Reverse Transcriptase designed for sensitive pathogen detection assays.

Henry Schein Presents THRIVELIVE 2024

Retrieved on: 
Tuesday, April 2, 2024
Medical Supplies, Health, Medical Devices, Other Health, Managed Care, Dental, Biotechnology, Multimedia, Knowledge, Dentistry, Sport, Practice management

Henry Schein, Inc. (Nasdaq: HSIC) announced today that it will host THRIVELIVE™ 2024, the Company’s annual dental event that celebrates innovation and community and provides a one-of-a-kind educational experience for dental professionals to learn how to grow their practices.

Key Points: 
  • Henry Schein, Inc. (Nasdaq: HSIC) announced today that it will host THRIVELIVE™ 2024, the Company’s annual dental event that celebrates innovation and community and provides a one-of-a-kind educational experience for dental professionals to learn how to grow their practices.
  • This year’s THRIVELIVE will take place at the Bellagio in Las Vegas, Nevada, from May 2-4, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240401917243/en/
    For the fourth consecutive year, THRIVELIVE will offer a comprehensive program designed to empower all dental professionals.
  • Unveiling Henry Schein Solutions: Discover the unique suite of services, solutions, and products offered by Henry Schein, specifically designed to support a dental practice's success.

Global Medical Adhesives & Sealants Market Report 2024 - Wide Array of Solutions and Application Areas Offered by Soft-Skin Adhesives Facilitating Market Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Medical Supplies, Health, Blood pressure, Adhesive, Dentistry, Growth, Prevalence, Vital signs, Patient, Conditional sentence, Radiation, Palliative care, Metal, Bacteria, Instrument, Electrode, Fibrin, Chronic radiation syndrome, Skin, Collagen, EKG, USB On-The-Go, Cosmetics, Acrylic

The "Global Medical Adhesives & Sealants Market - Resin Types, Applications and End-use Sectors" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Medical Adhesives & Sealants Market - Resin Types, Applications and End-use Sectors" report has been added to ResearchAndMarkets.com's offering.
  • The growth in demand for soft-skin adhesives has been made possible by the wide variety of their applications in the medical, pharmaceutical and personal care areas.
  • Soft-skin adhesives find application in a range of medical areas, which comprise skin therapies, wound dressing and wearable medical devices, providing further impetus to demand for them.
  • The range of applications for adhesives and sealants the medical sector includes the areas of dentistry & cosmetics, internal & external surgery and medical devices & equipment.

QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test

Retrieved on: 
Tuesday, April 2, 2024
Medical Supplies, FDA, Health, Infectious Diseases, COVID-19, General Health, VZV, Ageing, Food and Drug Administration, Research, Sale, Virus, SARS-CoV-2, Laboratory, CLIA, Multimedia, Data, Marketing, QuidelOrtho, Food

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho" or the “Company”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its QuickVue COVID-19 test.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho" or the “Company”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its QuickVue COVID-19 test.
  • This clearance allows the test to be used with accuracy and convenience in home and medical facility settings with CLIA certificates of waiver.
  • For healthcare providers, comprehensive instructions for use accompany the QuickVue COVID-19 test, facilitating seamless integration into existing diagnostic protocols.
  • QuidelOrtho secured FDA 510(k) clearance in December 2023 for its Savanna PCR platform and Savanna HSV 1+2/VZV PCR assay.

Global Disposable Gloves Market Outlook & Forecast 2024-2029, Featuring Key Vendors Ansell, Hartalega Holdings, Kossan Rubber Industries, Rubberex, Supermax, Top Glove and UG Healthcare - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Manufacturing, Other Manufacturing, Health, Chemicals, Plastics, Medical Supplies, Hospital, Research, Sanitation, Oil, Dentistry, Growth, Prevalence, Face, Agriculture, Mechanics, Beauty, COVID-19, Global health, Patient, Kossan Rubber Industries, Electronics, Health care, Latex, Laboratory, Surgeon, Infection, LaTeX, Water, Traction, Hygiene, Safety, B2B, Cosmetics, Neoprene, USD, Dentist, Medical device

The global disposable gloves market is characterized by dynamic and competitive forces shaped by supply and demand factors.

Key Points: 
  • The global disposable gloves market is characterized by dynamic and competitive forces shaped by supply and demand factors.
  • Prominent manufacturers include Ansell, Hartalega Holdings, Kossan Rubber Industries, Rubberex, Supermax, Top Glove, and UG Healthcare.
  • The global disposable gloves market, mainly fueled by the rising demand for nitrile gloves, stands at a pivotal juncture.
  • Disposable gloves have become indispensable in healthcare, food processing, manufacturing, and other sectors, shaping a robust market landscape in the region.

ZCG-Backed Unimed Appoints Simon Stadil as CFO

Retrieved on: 
Tuesday, April 2, 2024
Medical Supplies, Finance, Maritime, Transport, Banking, Professional Services, Health, Logistics, Supply Chain Management, Asset Management, Financial system, Growth, Ørsted (company), CFO, Copenhagen Business School, Knowledge, Welltec, Multimedia, Economics, Barclays, Silicon, Management

Universal Marine Medical Supply International (“Unimed” or the “Company”), the leading global provider of pharmaceutical and medical solutions to the maritime industry, today announced the appointment of Simon Stadil as Chief Financial Officer, effective April 1.

Key Points: 
  • Universal Marine Medical Supply International (“Unimed” or the “Company”), the leading global provider of pharmaceutical and medical solutions to the maritime industry, today announced the appointment of Simon Stadil as Chief Financial Officer, effective April 1.
  • “I’m thrilled to welcome Simon to the Unimed management team.
  • He is an ambitious and driven leader with diverse finance experience,” said Søren Andersen, CEO of Unimed.
  • Mr. Stadil has a B.Sc in economics and business administration as well as an M.Sc in finance and management accounting from Copenhagen Business School.

Study Finds C₂N Diagnostics’ PrecivityAD® Blood Test Provides Opportunities for Robust Cost Savings in the Evaluation of Patients with Cognitive Impairment

Retrieved on: 
Monday, April 1, 2024
Other Health, Seniors, Other Science, Pharmaceutical, Research, Mental Health, Medical Devices, Hospitals, Consumer, Science, Clinical Trials, Managed Care, Medical Supplies, Biotechnology, Neurology, Health, Health Technology, Health Insurance, Brain, Deficit spending, Cognitive deficit, CSF, Patient, Evaluation, PET, Biomarker, University, Population Health Management, Cerebrospinal fluid, Diagnosis, Pathology

The test helps healthcare providers better determine the presence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease.

Key Points: 
  • The test helps healthcare providers better determine the presence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease.
  • The new research, “ Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment ,” used a budget impact model in a hypothetical 1 million-member health plan to assess the economic utility of the PrecivityAD blood test.
  • Overall, the PrecivityAD blood test was associated with a cost savings of $643 per Alzheimer’s disease case (9% cost savings) identified.
  • We believe the use of the PrecivityAD blood test in the clinical care pathway may prevent unnecessary testing, provide cost savings and reduce the burden on both patients and health plans.”

AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

Retrieved on: 
Monday, April 1, 2024
Legal, Surgery, Medical Devices, Medical Supplies, Health Technology, Professional Services, Cardiology, Health, Oncology, Cancer, C.A, Patent, CAFC

Under the terms of the settlement, BD will grant a license to AngioDynamics under certain of BD’s port patents and AngioDynamics will grant BD a license under certain of AngioDynamics’ catheter patents.

Key Points: 
  • Under the terms of the settlement, BD will grant a license to AngioDynamics under certain of BD’s port patents and AngioDynamics will grant BD a license under certain of AngioDynamics’ catheter patents.
  • AngioDynamics will also make six minimum annual payments to BD of $2.5 million through February 2029, and potential additional payments if six percent (6%) of annual net sales of AngioDynamics’ port products exceed the minimum payment.
  • The parties will participate in the pending appeal before the Federal Circuit of the case titled C.R.
  • Neither party admitted any liability in connection with the settlement agreement.

Global Transdermal Medical Patch Market Analysis and Forecast to 2029: Growing Number of Smokers, Rising use for Insulin Delivery and Upswing in Hormonal Deficiencies Drives Demand - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Medical Supplies, Retail, Health, Tobacco, General Health, Pharmaceutical, Biotechnology, Hypersensitivity, Plasma, Obesity, Growth, Prevalence, Rheumatoid arthritis, Application, Incidence, Diabetes, Patient, Pharmacy, Conditional sentence, Chronic pain, Stroke, Hospital, Smoker, Cancer, Nature, Migraine, Distribution, Arthritis, Nausea, Diabetic neuropathy, Smoking, Skin, Pain management, Pain, Allergy, Market, Vomiting, Osteoarthritis, Ageing, Pharmaceutical industry

The "Global Transdermal Medical Patch Market: Analysis By Type, By Application, By Distribution Channel, By Region Size & Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Transdermal Medical Patch Market: Analysis By Type, By Application, By Distribution Channel, By Region Size & Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The global transdermal medical patch market was valued at US$7.88 billion in 2023 and is expected to reach US$10.33 billion by 2029.
  • The global transdermal medical patch market is highly competitive in nature, characterized by fierce competition among industry leaders vying to expand their market presence.
  • The key players in the global transdermal medical patch market are: